Concepedia

Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance

Jeong Eun Lee, Hee Sun Park, Dahye Lee, Geon Yoo, Tackhoon Kim, Haeyon Jeon, Min‐Kyung Yeo, Choong Sik Lee, Jae Young Moon, Sung Soo Jung,

Biochemical and Biophysical Research Communications · 2016 · 118 citations · 23 references

DOI

Concepts

References

23

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu et al. · Cancer Discovery · 2014 · 2.2K citations · Full text

, , +13

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

William Pao, Theresa Y. Wang, Gregory J. Riely et al. · PLoS Medicine · 2005 · 1.5K citations · Full text

, , +15

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhenfeng Zhang, Jae Cheol Lee, Luping Lin et al. · Nature Genetics · 2012 · 1.2K citations

, , +16

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

, , +17

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

Diane D. Shao, Wen Xue, Elsa Krall et al. · Cell · 2014 · 756 citations

, , +14